关键词: 胰腺癌, 化疗, 免疫治疗, 靶向治疗, 治疗策略

Abstract:

Interpretation of an updated treatment strategy for unresectable pancreatic adenocarcinoma        TENG Zan，LIU Yun-peng. Department of Medical Oncology，the First Hospital of China Medical University，Shenyang 110001，China
Corresponding author: LIU Yun-peng，E-mail：ypliu@cmu.edu.cn
Abstract    At present，the treatment strategy for unresectable pancreatic adenocarcinoma is mainly based on systemic chemotherapy and adopts local treatment such as radiotherapy，intervention，and palliative surgery as support，so as to relieve local symptoms，improve quality of life，and prolong survival of patients. It is suggested that patients with good performance status accept combination chemotherapy including FOLFIRINOX or gemcitabine (GEM) with nab-paclitaxel. With these treatments，the median survival of patients is extended to nearly 1 year and approximately 15% of locally advanced unresectable diseases have the opportunity to become resectable. Erlotinib plus gemcitabine combination therapy is still the only choice of target therapy in first-line treatment according to recommendation. There will be a promising breakthrough in Pegvorhyaluronidase alfa (PEGPH20) by improving the tumor microenvironment. PD-1/PD-L1 inhibitors are recommended for patients with previously treated MSI-H/dMMR unresectable pancreatic cancer by guidelines. Individualized precise treatment for cancer and multidisciplinary team (MDT) meetings are widely accepted and emphasized by guidelines.

Key words: pancreatic adenocarcinoma；chemotherapy；immunotherapy；targeted therapy, treatment strategy